Rexahn Pharmaceuticals

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders and other unmet medical needs. Our motto is "Saving Lives Through Innovation," which represents the Company's use of scientific innovation to improve the health and wellness of patients. We develop therapies that treat specific disease states, while minimizing side effects in order to help patients regain quality of life during treatment. Rexahn currently has a number of drug candidates in clinical development for cancer, CNS related disorders and sexual dysfunction. The Company's lead cancer candidate, Archexin (formerly named RX-0201) successfully completed Phase I clinical trials in 2006 and is in Phase II clinical trials for patients with advanced stage renal cell carcinoma (RCC), an abnormal growth of cells lining the tubules of the kidney. Additional Archexin clinical trials in gastrointestinal (GI) indications, such as pancreatic and stomach cancers, will follow. In the CNS area, Rexahn's drug candidate, Serdaxin for anxiety, and Zoraxel for sexual dydsfunction will enter Phase II clinical trials in 2007. Based on early studies, the compound appears to act on serotonin and dopamine, which are key neurotransmitters in the brain implicated in both of these conditions.

Contact Details: 9620 Medical Center Drive Rockville MD 20850 United States of America Tel: 240-268-5300 Fax: 240-268-5310 Email: info@rexahn.com WWW: www.rexahn.com/

Loading...

Recent Publications by Rexahn Pharmaceuticals:
QSID Tool: a new three-dimensional QSAR environmental tool. QSID Tool (Quantitative structure-activity relationship tool for...	31st May, 2008	Rexahn Pharmaceuticals, Inc., 9620 Medical Center Dr., Rockville, MD,	J Comput Aided Mol Des. 2008 May 30. DOI Direct Link

BioNews Results for Rexahn Pharmaceuticals:
FDA Approves Rexahn Phase II Trial	FDA News:  Sep 16 2008 10:57PM Matching: rexahn pharmaceuticals
Rexahn Pharmaceuticals Receives FDA Approval to Initiate Phase II Trial for Serdaxin in Patients with Major De	Pharma Live:  Sep 11 2008 3:40PM Matching: rexahn pharmaceuticals
Rexahn Pharmaceuticals Receives FDA Approval to Initiate Phase II Trial for Serdaxin in Patients with Major De	Therapeutics Daily:  Sep 11 2008 4:03AM Matching: rexahn pharmaceuticals
Rexahn wins approval to initiate Phase II study of depression drug	Therapeutics Daily:  Sep 11 2008 6:36PM Matching: rexahn pharmaceuticals
Rexahn Pharmaceuticals Receives FDA Approval to Initiate Phase II Trial for Serdaxin in Patients with Major De	PipelineReview:  Sep 11 2008 1:08PM Matching: rexahn pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Rexahn Pharmaceuticals news.

Rexahn Pharmaceuticals (RXHN.OB) Financial information Links from Barchart
RXHN.OB Quote from from Barchart.com
RXHN.OB Chart from from Barchart.com
RXHN.OB Profile from from Barchart.com
RXHN.OB Opinion from from Barchart.com
→View more Rexahn Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 290 times since April 2007, the link to the organisation's website has been followed 63 times

Recent Search Terms used to find this page: rexahn.com | info on rexahn | Rexahn email | REXAHN pharmaceuticals | qsid rexahn | qsar tool rexahn | rexahn pharmaceuticals | REXAHN PHARMACEUTICL | Serdaxin. | Serdaxin. | .

Search for more companies in Rockville

Search for more companies in MD

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Rexahn Pharmaceuticals